Bruce N. Jacobs sold $1.1M of KYMR
Chief Financial Officer at Kymera Therapeutics, Inc.. 12,471 shares at an average of $87.50, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 5.1% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.8%, 3m -15.0%, 6m +37.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-091982, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | AGrant or award Common Stock | +17,650 | $0.00 | $0 | 245,059 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -2,039 | $87.75 | $179k | 243,020 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -1,424 | $88.50 | $126k | 241,596 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock | -4,113 | $89.66 | $369k | 237,483 | Mar 4, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -492 | $84.00 | $41k | 236,991 | Mar 4, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -2,519 | $85.04 | $214k | 234,472 | Mar 4, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -1,437 | $85.78 | $123k | 233,035 | Mar 4, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -447 | $86.62 | $39k | 232,588 | Mar 4, 2026 |
| Mar 2, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +35,300 | $0.00 | $0 | 35,300 | Mar 4, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.